EVO Evotec SE

Nasdaq evotec.com


$ 3.17 $ 0.01 (0.31 %)    

Thursday, 13-Nov-2025 12:05:03 EST
QQQ $ 611.58 $ -6.10 (-0.99 %)
DIA $ 478.48 $ -2.88 (-0.6 %)
SPY $ 675.68 $ -4.80 (-0.71 %)
TLT $ 89.84 $ 0.04 (0.04 %)
GLD $ 386.64 $ -0.61 (-0.16 %)
$ 3.14
$ 3.22
$ 3.12 x 300
$ 3.20 x 100
$ 3.20 - $ 3.23
$ 2.84 - $ 5.64
110,410
na
278.76M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populationsFD...

 evotec-se-launches-share-repurchase-program-to-acquire-up-to-290k-shares-at-a-total-purchase-price-of-up-to-3-million

The management board of Evotec SE (Frankfurt Stock Exchange, TRQX:EVTd, ISIN: US30050E1055) resolved on 6 November 2025 to impl...

 evotec-affirms-fy2025-sales-guidance-of-861690m-907042m

Evotec (NASDAQ:EVO) affirms FY2025 sales outlook from $861.690 million-$907.042 million to $861.690 million-$907.042 million.

 evotec-q3-eps-014-inline-sales-191620m-miss-237320m-estimate

Evotec (NASDAQ:EVO) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 16.67 pe...

Core News & Articles

Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, TRQX:EVTd(TRQX:EVTdFTRQX:EVTdrTRQX:EVTdaTRQX:EVTdnTRQX:EV...

Core News & Articles

Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continue...

 hc-wainwright--co-maintains-buy-on-evotec-lowers-price-target-to-7

HC Wainwright & Co. analyst Douglas Tsao maintains Evotec (NASDAQ:EVO) with a Buy and lowers the price target from $8 to...

 evotec-guides-2025-revenues-at-760m800m-adjusted-ebitda-at-30m50m-rd-spend-seen-at-40m50m

Guidance for full-year 2025Group revenues expected in a range of € 760 - 800 m (2024: € 797.0 m)R&D expenditures are expect...

 an-overview-of-evotecs-earnings
An Overview of Evotec's Earnings
08/12/2025 16:01:38

Core News & Articles

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to SandozUn...

 evotec-cuts-2025-revenue-forecast-to-760m800m-from-prior-840m-880m-amid-shifting-revenue-mix-and-weak-rd-market

Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480, NASDAQ:EVO) announce...

 evotecs-collaboration-sparks-hope-for-acute-kidney-injury-breakthroughs

Evotec shares rise after joining NURTuRE-AKI to advance kidney disease research through molecular data integration.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION